

Review

Not peer-reviewed version

Interplay Between the Circadian Clock and Sirtuins

Yan Zhuang , Yantong Zhang , [Chao Liu](#) ^{*} , [Yingbin Zhong](#) ^{*}

Posted Date: 16 September 2024

doi: 10.20944/preprints202409.1202.v1

Keywords: circadian clock; circadian rhythm; clock gene; sirtuin; metabolism



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Review

Interplay between the Circadian Clock and Sirtuins

Yan Zhuang ¹, Yantong Zhang ², Chao Liu ^{2,*} and Yingbin Zhong ^{1,3,*}

¹ School of Basic Medical Sciences, Suzhou Medical College of Soochow University, Suzhou 215123, China

² School of Life Sciences, Suzhou Medical College of Soochow University, Suzhou, Jiangsu 215123, China

³ MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Medical College of Soochow University, Suzhou 215123, China

* Correspondence: liuchao@suda.edu.cn(C.L.); ybzhongsd@suda.edu.cn (Y.Z.)

Abstract: The circadian clock is an autonomous timekeeping system evolved by organisms to adapt to external changes, regulating a variety of important physiological and behavioral processes. Recent studies have shown that the sirtuin family of histone deacetylases is involved in regulating the expression of clock genes and plays an important role in maintaining the normal rhythm of clock gene expression and behavior. Moreover, sirtuins are regulated directly or indirectly by the circadian clock system. The mutual regulation between the circadian clock and sirtuins is likely involved in a variety of signal transduction and metabolism processes. In this review, we discuss the molecular mechanisms and research progress on the intertwined relationship between the circadian clock and sirtuins, highlighting sirtuins as molecular links between metabolic control and circadian rhythms and offering our perspectives on future developments in the field.

Keywords: circadian clock; circadian rhythm; clock gene; sirtuin; metabolism

1. Introduction

The rotation of the Earth has resulted in daily changes in environmental factors, such as light, temperature, and food. This is a challenge that all life on Earth must face. To adapt to these daily environmental changes and efficiently utilize energy to maintain homeostasis, most organisms on Earth, including bacteria, algae, fungi, plants, and animals, have evolved a circadian clock system to anticipate and respond effectively to daily changes[1-6]. Thus, the circadian clock is an intrinsic timekeeping system that evolved in organisms as a long-term adaptation to periodic changes in the external environment[7, 8]. The circadian clock is able to run even under constant environmental conditions with an approximately 24-h periodicity. It regulates various physiological and behavioral activities, such as sleep, eating, hormone secretion, immunity, and cellular metabolism[9-11]. The circadian clock is genetically controlled, and alteration or disruption of the circadian clock can change the rhythmic physiology and behavior of animals and have detrimental effects on human health[11-13].

Sirtuins are a class of NAD⁺-dependent histone deacetylases (HDACs) that play important biological roles within cells[14]. This family was first named for its representative member in yeast, silent information regulator 2 (Sir2), and has been widely found in a wide range of organisms, including mammals[15]. Sir2 homologous proteins found in various species are collectively referred to as the sirtuin family, and the mammalian sirtuin family includes seven members (SIRT1--7) that have different subcellular localizations and functions[16]. These proteins play important roles in processes such as cell apoptosis, mitochondrial biogenesis, lipid metabolism, fatty acid oxidation, cellular stress, insulin secretion, and aging[17, 18].

Recent studies have shown that the sirtuin family, which regulates various energy metabolism pathways, is related to the expression of clock genes[19-21]. Moreover, the circadian clock directly regulates the rhythmic transcription of *sirt1* and indirectly modulates the circadian activity of sirtuins through regulating the transcription of *Nampt*[22]. These findings implicate certain interactions between the circadian clock and sirtuins. Therefore, further study into their mutual regulation will reveal the close connection between the circadian clock and the metabolic network.

2. The Circadian Clock System and Molecular Architecture

The circadian clock system in mammals generally consists of three parts: the input or entrainment pathway, the central pacemaker or oscillator, and the output pathway[23]. The input pathway is responsible for sensing changes in external light and dark, temperature, and other time cues (so-called zeitgebers) and converting them into neural signals that are transmitted to the central pacemaker or oscillator. The central pacemaker or oscillator generates molecular oscillations of clock genes and their related proteins in response to transmitted signals. Finally, the output pathway regulates downstream physiological and behavioral activities through these oscillations. In mammals, the circadian timekeeping system is composed of a central pacemaker in the suprachiasmatic nucleus (SCN) of the hypothalamus and subsidiary oscillators in most peripheral tissues[24-26]. The main zeitgeber of the central pacemaker is the periodic change in light and dark, whereas the zeitgeber of peripheral tissues is subjected mostly to cyclic feeding behavior [1, 2, 27, 28]. The pacemaker SCN entrains to the environmental light/dark cycle via photic input from the retinohypothalamic tract (RHT). In turn, the SCN both directly and indirectly maintains the synchrony of peripheral oscillators through various entrainment mechanisms [27-30]. Furthermore, the peripheral circadian clock can independently regulate the expression of genes associated with tissue-specific functions, allowing their rhythms to exhibit a certain degree of tissue specificity [31].

The maintenance of circadian rhythms by the circadian clock depends on conserved clock genes and clock-controlled genes. Approximately 10% of gene expression is rhythmic in a given tissue[32, 33]. The molecular architectures of the core circadian clock and peripheral tissue circadian clock are essentially the same. Both rely on interlocking transcription-translation feedback loops (TTFLs) (Fig. 1)[2, 34, 35]. In the core of these loops, the basic helix-loop-helix (bHLH)-Per-Arnt-Sim (PAS) transcription factors BMAL1 and CLOCK form heterodimers to promote the transcription of genes with an E-box in their promoter and/or enhancer regions, including clock genes *Period* (*Per1*, *Per2*, *Per3*), *Cryptochrome* (*Cry1*, *Cry2*), *Rev-erb α/β* , *Rora $\alpha/\beta/\gamma$* , and *D-box binding protein* (*Dbp*), thereby increasing the translation and accumulation of the corresponding proteins in the cytoplasm[2, 23]. PER and CRY form a repressive complex with casein kinase 1 ϵ/δ (CK1 ϵ/δ), and the complex enters the nucleus and binds to CLOCK-BMAL1 heterodimers to form a tetra complex to inhibit the transcriptional activity of CLOCK-BMAL1, thereby repressing their own expression[36-38]. In the second interlocked loop, the REV-ERB/ROR-binding element (RRE) in the promoter region, regulating the transcription of *Clock*, *Bmal1*, and *Nfil3*[25, 36]. In the last interlocked loop, DBP activates while NFIL3 inhibits the expression of *Rora $\alpha/\beta/\gamma$* through the D-box, increasing the complexity of the entire negative feedback transcriptional regulatory mechanism[39-42]. These loops also control the expression of clock-controlled genes (*Ccgs*), which mediate circadian output[11].

In addition to transcriptional activators and repressors, the posttranslational modifications and degradation of circadian clock proteins are key steps in the regulation of the circadian clock (Fig. 1). The phosphorylation of PER proteins is mediated by casein kinase 1 δ/ϵ (CK1 δ/ϵ)[43-45], and these phosphorylation events regulate the sensitivity of PER to proteasomal degradation mediated by the E3 ligase β -TrCP (also known as F-box/WD repeat-containing protein 1A)[46, 47]. Similarly, the phosphorylation of CRY1 and CRY2 induced by AMP-activated protein kinase (AMPK) also affects their stability[48]. Phosphorylated CRY1 and CRY2 become targets of the E3 ubiquitin ligases FBXL3 and FBXL21 and are ultimately degraded[49, 50].




Figure 1. Molecular architecture of the core and interlocked feedback loops in mammals. At the core of these loops, BMAL1 and CLOCK form a heterodimeric transcriptional activator complex that binds to E-box motifs at promoters and enhancers to activate the transcription of the *Per1*, *Per2*, *Per3*, *Cry1*, and *Cry2* genes. PER and CRY form heterodimers and suppress their own transcription by inhibiting CLOCK-BMAL1 transcriptional activity. The second feedback loop is composed primarily of *Rev-erba*, which serves as a direct target of the CLOCK-BMAL1 transcriptional activator complex. REV-ERBa provides negative feedback by inhibiting the transcription of *Bmal1* and competes with the retinoic acid-related orphan receptor (ROR) for binding to REV-ERB/ROR-binding elements (RREs) within the *Bmal1* promoter. In the last loop, NFIL3 and DBP inhibit and activate the expression of D-box genes, respectively, to regulate the rhythm of ROR nuclear receptors. All loops also control the expression of clock-controlled genes (Ccgs), which mediate circadian output. Selected factors that mediate posttranslational modifications and degradation of specific clock proteins are shown. The arrows depict the synthesis, assembly and/or localization of clock proteins; the blocked line denotes repression; BMAL1, also known as ARNTL; CK1, casein kinase 1; AMPK, AMP-activated protein kinase; P, phosphorylation; E, E-box; RRE, REV-ERB/ROR response element; Ub, ubiquitylation.

3. Sirtuins and Their Biological Functions

Sirtuins (SIRT1-7) all belong to the same category of HDACs, and the overall structure of the HDAC domain is similar in all isoforms. The structure of sirtuin proteins usually consists of two main domains: a large Rossmann fold domain and a small domain containing a zinc-binding module[51]. These two structural domains are highly conserved among all subtypes of the sirtuin family. Its large Rossmann fold domain is related to NAD⁺ binding and catalytic acetyl group removal, whereas the small zinc-binding module provides support for protein stability and substrate binding[52]. These structural features constitute the key basis for sirtuin family proteins regulating various cellular processes[53]. The seven members of the mammalian sirtuin family have different subcellular localizations and regulate different cellular functions, with SIRT1 and SIRT2 being found both in the nucleus and the cytoplasm; SIRT6 and SIRT7 being nuclear proteins; and SIRT3, SIRT4 and SIRT5 mitochondrial proteins, in a cell- and tissue-dependent context [54-56]. Studies have shown that SIRT1-3 have strong deacetylase activity, SIRT4-7 have weak or undetectable deacetylase activity, and SIRT4 mainly exhibits ADP-ribosyltransferase activity[57].

SIRT1 has the highest degree of homology with Sir2 and is the most comprehensively studied member of this family. It has classically been thought to be a nuclear protein, and studies have also shown that SIRT1 is localized to the cytoplasm as well[58]. SIRT1 requires NAD⁺ as a coenzyme, and the removal of each acetyl group results in the consumption of one molecule of NAD⁺ and the formation of nicotinamide and O-acetyl-ADP-ribose (OAADPr)[59]. SIRT1 interacts with histones and some nonhistone substrates to regulate important physiological processes, such as glucose metabolism, fat metabolism, insulin secretion, angiogenesis, and cellular aging[60, 61]. Its role in oxidative stress and redox signaling has also been well studied[62].

SIRT2 is localized mainly in the cytoplasm to deacetylate α -tubulin and transiently migrates to the nucleus to deacetylate H4K16 during the G2/M transition [63, 64]. Its functions involve regulating the cell cycle, neurodegeneration, tumor suppression, and inflammation[65-67]. Studies have shown that SIRT2 deacetylates FOXO1 and FOXO3 [68], which connect SIRT2 with DNA repair, apoptosis, metabolism, and aging[69]. SIRT2 also deacetylates PGC-1 α , thereby modulating mitochondrial biogenesis[70].

SIRT3 is a key regulatory factor of mitochondrial function that is highly expressed in metabolically active tissues[71]. It is abundant in mitochondria and regulates energy production and the oxidative stress response[72, 73]. SIRT3 directly interacts with glutamate dehydrogenase (GDH) and ornithine transcarbamylase (OCT) in mitochondria; regulates liver lipids, glycolysis, and the urea cycle; and protects the liver[74]. It indirectly regulates the accumulation of reactive oxygen species (ROS) by acetylating mitochondrial superoxide dismutase (SOD2) and isocitrate dehydrogenase 2 (IDH2), thereby inhibiting the transcriptional activity of hypoxia-inducible factor 1 α (HIF-1 α) and resisting oxidative stress[75]. SIRT3 is the only member of the sirtuin family for which direct evidence exists regarding the increase in longevity in humans[76].

SIRT4 is located in mitochondria, but it has weak deacetylase activity and relies mainly on its ADP-ribosyltransferase activity to regulate glutamine metabolism, thereby promoting the breakdown of branched-chain amino acids and fat formation and inhibiting insulin secretion and liver fatty acid oxidation[77, 78]. Recently, SIRT4 was found to deacetylate lysine residues, controlling leucine metabolism and insulin secretion[79]. In addition, SIRT4 also regulates the DNA damage response and prevents the occurrence of tumors[80].

SIRT5 is also localized in the mitochondrial matrix, where it deacetylates, demalonylates, desuccinylates, and deglutarylates multiple proteins[76, 81, 82]. It is known for its ability to regulate mitochondrial fatty acid oxidation, the urea cycle, and cellular respiration[83, 84]. SIRT5 has been shown to play roles in cellular metabolism, detoxification, the regulation of oxidative stress, energy production, and the mediation of the apoptosis pathway[85-90].

SIRT6 is a nuclear sirtuin. It has histone deacetylation and ADP ribosylation functions and plays an important role in chromatin regulation and gene expression[91-94]. SIRT6 is involved in DNA repair, antiinflammation, antioxidant defense, glucose metabolism, lipid metabolism, and cancer[95-102]. Studies on mouse models have revealed that SIRT6 is related to mouse lifespan[76, 103, 104].

SIRT7, the last member of the currently identified mammalian sirtuin family, is also located in the cell nucleus. It is specifically expressed in the nucleoli, where it deacetylates H3K18 and desuccinylates H3K122 to modulate chromatin remodeling, gene transcription and DNA repair[105-107]. SIRT7 participates in cellular stress by inhibiting the activity of hypoxia-inducible factors [108], acts as an auxiliary factor for the inhibition of oncogene transcription[109], and plays a role in mammalian aging[76, 110-112]. SIRT7 can also regulate some mitochondrial functions by deacetylating the GABP-beta 1 protein[113].

4. Regulation of Sirtuins by the Circadian Clock

The circadian clock system, through the rhythmic expression of clock genes and clock-controlled genes, is widely involved in the regulation of various physiological processes, such as lipid metabolism, cholesterol synthesis, glucose metabolism and transport, and oxidative phosphorylation, and plays an important regulatory role in metabolism[114-116]. NAD⁺, a coenzyme

of sirtuins, is a rhythmic metabolite regulated by the circadian clock that plays a crucial role in linking the circadian clock with sirtuins[117, 118].

The intracellular level of NAD⁺ is maintained by the tryptophan de novo synthesis pathway or the NAD⁺ salvage pathway controlled by the rate-limiting enzyme nicotinamide phosphoribosyltransferase (NAMPT)[119, 120]. Both the expression of *Nampt* RNA and the NAMPT protein display a diurnal pattern of oscillation[117, 118]. Further study revealed that *Nampt* is a clock-controlled gene and that the circadian clock regulates the circadian expression of *Nampt* by binding the CLOCK-BMAL1 heterodimer to the promoter of *Nampt* (Fig. 2)[117, 118]. Therefore, the rhythmic expression of *Nampt* is the cause of circadian oscillation of NAD⁺[117, 118]. The specific pathway is as follows: the CLOCK-BMAL1 heterodimer binds to the E-box promoter element of the *Nampt* gene to promote *Nampt* expression; NAMPT catalyzes the rate-limiting step of the production of the intermediate nicotinamide mononucleotide (NMN) from NAM; and finally, this intermediate, NMN, is converted to NAD⁺ by NMNAT1-3 (Fig. 2). Hence, the rhythmic activity of sirtuins is regulated by the oscillating levels of the intracellular metabolite NAD⁺, which emphasizes the importance of the circadian clock in the control of sirtuin activity and metabolism.




Figure 2. The mutual regulatory mechanism between sirtuins and the circadian clock. The circadian clock regulates the activity of sirtuins through multiple mechanisms, including indirectly modulating sirtuin activity by controlling the rhythmic expression of *Nampt* to regulate NAD⁺ oscillation levels and directly influencing the transcription of the *Sirt1* or SIRT1 protein. SIRT1, in turn, interacts with CLOCK-BMAL1 to affect circadian rhythm amplitude and gene expression by deacetylating PER2, BMAL1, and histone H3 at circadian gene promoters. In contrast to SIRT1, SIRT6 interacts with CLOCK-BMAL1 and governs its chromatin recruitment to circadian gene promoters. SIRT6 can also affect the circadian clock by deacetylating PER2, whereas SIRT7 contributes to circadian clock regulation by deacetylating CRY1. NAM, nicotinamide; NMN, nicotinamide mononucleotide; NAMPT, nicotinamide phosphoribosyltransferase; NMNAT1-3, nicotinamide mononucleotide adenylyltransferase; Ac, acetylation; dashed lines represent rhythmic mRNAs; arrows depict the synthesis, assembly and/or localization of clock proteins; the blocked line denotes repression.

In addition to regulating *Nampt* transcription to affect sirtuin activity, the circadian clock can also directly regulate the transcription of *Sirt1* through the binding of the CLOCK-BMAL1 heterodimer to the E-box region of the *Sirt1* promoter[121]. The overexpression of the clock genes

Bmal1 and *Clock* in mouse liver cells can promote the accumulation of SIRT1, and interference with or mutation of *Clock* can decrease the expression levels of *Sirt1* mRNA and protein[121]. However, it has been reported that not *Sirt1* mRNA levels but rather SIRT1 protein levels accumulate in a circadian manner, with maximal and minimal levels reached at approximately Zeitgeber time (ZT) 16 and ZT4 in the mouse liver, respectively[19]. These controversial findings require further investigation. Interestingly, SIRT1 is recruited to the *Nampt* promoter with CLOCK-BMAL1, thus contributing to the synthesis of its own coenzyme NAD⁺[117]. In addition to SIRT1, whether other sirtuins are directly regulated by the circadian clock needs further investigation. Overall, the role of sirtuins in metabolism and their activity regulated by the circadian clock closely links the circadian clock with metabolic regulation.

5. Regulation of the Circadian Clock by Sirtuins

Early research on the cellular oxidation status demonstrated the impact of metabolism on the function of the circadian clock[122]. For example, the DNA binding activity of the CLOCK-BMAL1 heterodimer is affected by the intracellular redox state and the relative ratio of NAD(P)H/NAD(P)⁺, with high levels of NAD(P)H increasing the binding ability of CLOCK-BMAL1 to E-box elements[123].

Research has shown that the NAD⁺-dependent histone deacetylase SIRT1 directly regulates the acetylation status of clock components and affects the amplitude of circadian rhythms in cells and the liver (Fig. 2 and Table 1)[124]. SIRT1 interacts with CLOCK and periodically regulates the acetylation of BMAL1 and histone H3, and the loss of *Sirt1* increases the amplitude of circadian rhythms[20]. These findings were confirmed by the pharmacological activation or inhibition of SIRT1 activity (Table 2)[20, 117, 118, 125]. Moreover, inhibition of NAMPT activity by FK866 has effects on the circadian clock similar to those of the inhibition of SIRT1 (Table 2)[20, 117, 118]. These findings suggest that SIRT1 functions as a negative regulator of BMAL1 and circadian components. However, Asher *et al.* reported that SIRT1 deacetylates PER2 and promotes its degradation and that the loss of *Sirt1* decreases the amplitude of circadian rhythms through PER2 acetylation[19]. Thus, SIRT1 functions as a positive regulator. Similar results were reported in neuronal cells, in which SIRT1 deacetylates BMAL1 and directly activates the transcription of *Bmal1* via PGC-1 α to increase its expression amplitude[126]. These seemingly controversial results may be due to the different cell systems employed. In addition to its role in peripheral circadian control, SIRT1 also functions in the SCN. Brain-specific *Sirt1* knockout mice display reduced activity and prolonged period of behavior rhythmicity, whereas brain-specific overexpression of *Sirt1* has the opposite effects[126]. Overall, these findings suggest that SIRT1 is physically associated with the CLOCK-BMAL1 complex [19, 20], thereby participating in the regulation of the circadian clock feedback loop[117, 118]. Therefore, SIRT1 appears to operate as a rheostat of the circadian system.

In contrast to SIRT1, SIRT6 interacts with CLOCK-BMAL1 and governs its chromatin recruitment to circadian gene promoters[127]. However, these two sirtuins independently interact with the clock machinery[127]. Thus, controlling circadian gene expression via SIRT6 and SIRT1 appears to define unique subdomains of oscillating CCGs that are involved in distinct biological functions[127]. Moreover, SIRT6 controls circadian chromatin recruitment of SREBP-1, resulting in the cyclic regulation of genes implicated in fatty acid and cholesterol metabolism [127]. It has also been reported that SIRT6 interacts with and deacetylates PER2, preventing its proteasomal degradation, and the loss of *Sirt6* altered the oscillation of BMAL1 and PER2 mRNA and protein levels [128]. The opposite effects of SIRT1 and SIRT4 on PER2 may be due to the presence of multiple acetylation sites within the PER2 protein.

Finally, another sirtuin, SIRT7, has been reported to deacetylate CRY1 in the mouse liver, thereby promoting its degradation to regulate the hepatic clock and glucose homeostasis[129].

Table 1. Effects of genetic manipulation of sirtuins on the circadian clock.

Gene Manipulation	Cell/Tissue/Organism	Phenotype	References
SIRT1 overexpression	NIH3T3	Increased magnitude oscillation of the <i>Bmal1</i> -, <i>Per2</i> -, <i>Dbp:luciferase</i> reporter	[19]
		Decreased PER2 acetylation and increased PER2 degradation	[19]
	JEG3	Repressed CLOCK:BMAL1-driven <i>Per1:luciferase</i>	[125]
	HEK293	Suppressed CLOCK:BMAL1-driven <i>Per2:luciferase</i>	[118]
SIRT1 H363Y (enzyme activity dead mutation) overexpression	NIH3T3	Suppressed the expression and the oscillation of <i>Per2</i>	[118]
		Abolished oscillation of the <i>Bmal1:luciferase</i> reporter	[19]
Brain-specific SIRT1 overexpression	Mouse	Increased behavior activity and shortened period	[126]
	Mouse SCN	Restored ability to adapt to changes in the light entrainment schedule in aged mice	[126]
Knockdown	NIH3T3	Upregulated the expression of clock genes	[126]
	N2a	Attenuated circadian oscillations of the <i>Bmal1</i> -, <i>Per2</i> -, <i>Dbp:luciferase</i> reporter	[19]
<i>Sirt1</i>	N2a	Increased PER2 acetylation and protein level	[19]
		Reduced transcript and protein levels of clock genes	[126]
Knockout	Mouse MEFs	Attenuated circadian oscillations of the <i>Bmal1</i> -luciferase reporter, modest phase advance for the temporal expression of <i>Bmal1</i> -, <i>Per2</i> -, and <i>Dbp:luciferase</i>	
		Reduced oscillation of <i>Bmal1</i> , <i>Clock</i> , <i>Per1</i> , <i>Cry1</i> , <i>Per2</i> and <i>Rory</i> mRNA expression level	[19]
		Reduced oscillation of BMAL1, CLOCK and elevated PER2, CRY1 protein level	[19]
		Increased PER2 acetylation and stability	[19]
		Increased the transcription levels and broadened the oscillation cycles of <i>Dpb</i> and <i>Per2</i>	[20]
			[20]
Liver-specific knockout	Mouse Liver	Increased and altered circadian histone H3 (Lys9/Lys14) acetylation levels	
		Increased and altered circadian BMAL1 (Lys537) acetylation levels	
Brain-specific knockout	Mouse	Increased and altered circadian BMAL1 (Lys537) acetylation levels	
		Increased expression levels of the CCGs <i>Dbp</i> and <i>Nampt</i> and enhanced oscillation of NAD ⁺	[20, 125]
Brain-specific knockout	Mouse	Reduced behavior activity and elongated period	[126]
		Reduced ability to adapt to changes in the light entrainment schedule in young mice	[126]

			Downregulated the expression of clock genes	
		HEK293	Reduced PER2 protein level and stability and increased PER2 acetylation	[128]
			Increased mRNA abundance of <i>Bmal1</i> and <i>Per2</i>	[128]
		Mouse MEFs	Advanced phase of <i>Bmal1</i> , <i>Per2</i> and <i>Cry1</i>	[128]
			Increased BMAL1 but decreased PER2 protein oscillation level	[128]
<i>Sirt6</i>	Knockout		Reduced PER2 protein level	[128]
			Altered circadian transcriptome	
			Enhanced association of BMAL1 to chromatin and increased circadian BMAL1 occupancy at the <i>Dpb</i> and <i>Per1</i> promoter	[127]
		Mouse liver	Increased Ac-H3K9 across all time points	[127]
			Highly enriched SREBP binding sites	[127]
			Altered circadian rhythmicity of genes and metabolites related to fatty acid metabolism	[127]
<i>Sirt7</i>	Knockout	Mouse liver	Advanced liver circadian phase Increased the acetylation level of CRY1	[129]

Table 2. Effects of pharmacological manipulation of SIRT1 and NAMPT on the circadian clock.

Target	Manipulation	Medicine	Cell/Tissue	Phenotype	References
		NAM	NIH3T3	Dampened circadian <i>Bmal1:luciferase</i> expression and lengthened period	[19]
		Sirtinol	NIH3T3	Dampened circadian <i>Bmal1:luciferase</i> expression	[19]
	Inhibition	Splitomicin and NAM	Mouse MEFs	Increased the transcription levels and broadened the oscillation cycle of <i>dpb</i>	[20]
				Increased and altered circadian Ac-H3 (Lys9/Lys14) levels	[20]
		EX-527 or NAM	HEK293	Activated <i>Per2:luciferase</i> transcription	[118]
		SRT2183 and NAD ⁺	Mouse MEFs	Decreased <i>Per2</i> transcription and amplitude	[125]
SIRT1				Reduced Ac-H3 binding to <i>Per2</i> and <i>Dpb</i> promoter	[125]
		SRT1720	Mouse liver	Suppressed expression of <i>Per2</i> , <i>Dpb</i> , and <i>Nampt</i>	[125]
				Reduced recruitment of CLOCK and Ac-H3 on <i>Dbp</i> promoter	[125]
	Activation	SRTCD1023 and SRTCL1015	U2OS and NIH3T3	Reduced amplitude of both <i>Bmal1</i> : and <i>Per2:luciferase</i>	[125]
			Mouse MEFs	Repressed expression of <i>Per2</i> and <i>Cry1</i>	[125]
				Reduced CLOCK binding to <i>Per2</i> and <i>Dpb</i> promoter	[125]
		Resveratrol	HEK293	Inhibited <i>Per2:luciferase</i> transcription	[118]
NAMPT	Inhibition	FK866	Mouse MEFs	Advanced phase and increased amplitude of <i>Per2</i> and <i>Dbp</i>	[117]
					[117]

	Increased and broadened peak of circadian Ac-BMAL1 (Lys537) levels	[118]
	Increased transcription <i>Per2:luciferase</i>	
Mouse		
primary	Damped <i>Per2</i> oscillation	[118]
hepatocytes		

6. Concluding Remarks

Although some interactions between the circadian clock and sirtuins have been established, there is still a limited understanding of the precise regulatory mechanisms involved. For example, in addition to SIRT1, whether and how are other sirtuins directly regulated by the circadian clock? Are there any possible mechanisms by which sirtuins regulate the circadian clock? Interestingly, SIRT1, SIRT6, and SIRT7, which have been demonstrated to regulate the circadian clock by directly regulating clock gene expression or clock component acetylation, are all localized in the nucleus or cytoplasm [19, 20, 126-129]. However, the roles of the sirtuins SIRT3, SIRT4, and SIRT5, which are localized in the mitochondria, in the circadian clock have not been studied. The involvement of mitochondrial sirtuins in circadian regulation, as well as their regulatory mechanisms, remains to be further explored.

Circadian control of metabolism is thought to be critical for organismal homeostasis [130, 131]. Disruption of the circadian clock may lead to the occurrence of metabolic diseases, such as hyperglycemia, type 2 diabetes, and hypertension [40, 132]. Metabolism is one of the regulatory targets of the circadian clock, which can also feedback to modulate clock function. Accumulating evidence reveals intriguing interactions between the circadian clock and cellular metabolism [133-138]. Sirtuins are particularly notable for their role in regulating cellular metabolism [56, 139, 140]. Consequently, sirtuins are considered potential therapeutic targets and are the focus of research related to metabolic diseases and aging [141-143]. The complex mutual regulatory process between sirtuins and the circadian clock suggests that there is an interlocked transcriptional–enzymatic feedback loop that governs the molecular interplay between cellular metabolism and circadian rhythms [20, 117, 118]. More research is needed on the interaction between the circadian clock and sirtuins, as well as their potential therapeutic mechanisms in metabolic diseases. These studies will help elucidate the importance of the interplay between the circadian clock and sirtuins in maintaining metabolism homeostasis, providing new targets and strategies for the treatment of metabolic diseases.

Author Contributions: Y.Z, C.L, Y-b.Z contributed to the conceptualization and writing of the manuscript. Y.Z and Y-t.Z assembled the figures. All authors reviewed and/or edited the article before submission.

Acknowledgments: This work was supported by grants from the National Key R&D Program of China (2019YFA0800400), the National Natural Science Foundation of China (NSFC) (31871186), the Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions (YX13400214), the Hui-Chun Chin and Tsung-Dao Lee Chinese Undergraduate Research Endowment (CURE), and the open project program of the Key Laboratory of Loach Genetics and Breeding of Jiangsu Province.

Conflicts of Interest: The authors declare that they have no conflicts of interest related to the contents of this article.

References

1. Albrecht, U.; Eichele, G., The mammalian circadian clock. *Current opinion in genetics & development* **2003**, *13*, (3), 271-7.
2. Reppert, S. M.; Weaver, D. R., Coordination of circadian timing in mammals. *Nature* **2002**, *418*, (6901), 935-41.
3. Hurd, M. W.; Ralph, M. R., The significance of circadian organization for longevity in the golden hamster. *Journal of biological rhythms* **1998**, *13*, (5), 430-6.

4. Ouyang, Y.; Andersson, C. R.; Kondo, T.; Golden, S. S.; Johnson, C. H., Resonating circadian clocks enhance fitness in cyanobacteria. *Proceedings of the National Academy of Sciences of the United States of America* **1998**, *95*, (15), 8660-4.
5. Pittendrigh, C. S.; Minis, D. H., Circadian systems: longevity as a function of circadian resonance in *Drosophila melanogaster*. *Proceedings of the National Academy of Sciences of the United States of America* **1972**, *69*, (6), 1537-9.
6. Woelfle, M. A.; Ouyang, Y.; Phanvijhitsiri, K.; Johnson, C. H., The adaptive value of circadian clocks: an experimental assessment in cyanobacteria. *Current biology : CB* **2004**, *14*, (16), 1481-6.
7. Pittendrigh, C. S., Temporal organization: reflections of a Darwinian clock-watcher. *Annual review of physiology* **1993**, *55*, 16-54.
8. Sehgal, A., Physiology Flies with Time. *Cell* **2017**, *171*, (6), 1232-1235.
9. Bass, J.; Takahashi, J. S., Circadian integration of metabolism and energetics. *Science* **2010**, *330*, (6009), 1349-54.
10. Dunlap, J. C., Molecular bases for circadian clocks. *Cell* **1999**, *96*, (2), 271-90.
11. Patke, A.; Young, M. W.; Axelrod, S., Molecular mechanisms and physiological importance of circadian rhythms. *Nature reviews. Molecular cell biology* **2020**, *21*, (2), 67-84.
12. Young, M. W.; Kay, S. A., Time zones: a comparative genetics of circadian clocks. *Nature reviews. Genetics* **2001**, *2*, (9), 702-15.
13. Zhang, R.; Lahens, N. F.; Ballance, H. I.; Hughes, M. E.; Hogenesch, J. B., A circadian gene expression atlas in mammals: implications for biology and medicine. *Proceedings of the National Academy of Sciences of the United States of America* **2014**, *111*, (45), 16219-24.
14. Michan, S.; Sinclair, D., Sirtuins in mammals: insights into their biological function. *The Biochemical journal* **2007**, *404*, (1), 1-13.
15. Blander, G.; Guarente, L., The Sir2 family of protein deacetylases. *Annu Rev Biochem* **2004**, *73*, 417-35.
16. Houtkooper, R. H.; Pirinen, E.; Auwerx, J., Sirtuins as regulators of metabolism and healthspan. *Nature reviews. Molecular cell biology* **2012**, *13*, (4), 225-238.
17. Bonkowski, M. S.; Sinclair, D. A., Slowing ageing by design: the rise of NAD(+) and sirtuin-activating compounds. *Nature reviews. Molecular cell biology* **2016**, *17*, (11), 679-690.
18. Fang, Y.; Tang, S.; Li, X., Sirtuins in Metabolic and Epigenetic Regulation of Stem Cells. *Trends in endocrinology and metabolism: TEM* **2019**, *30*, (3), 177-188.
19. Asher, G.; Gatfield, D.; Stratmann, M.; Reinke, H.; Dibner, C.; Kreppel, F.; Mostoslavsky, R.; Alt, F. W.; Schibler, U., SIRT1 regulates circadian clock gene expression through PER2 deacetylation. *Cell* **2008**, *134*, (2), 317-28.
20. Nakahata, Y.; Kaluzova, M.; Grimaldi, B.; Sahar, S.; Hirayama, J.; Chen, D.; Guarente, L. P.; Sassone-Corsi, P., The NAD⁺-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. *Cell* **2008**, *134*, (2), 329-40.
21. Peek, C. B.; Affinati, A. H.; Ramsey, K. M.; Kuo, H. Y.; Yu, W.; Sena, L. A.; Ilkayeva, O.; Marcheva, B.; Kobayashi, Y.; Omura, C.; Levine, D. C.; Bacsik, D. J.; Gius, D.; Newgard, C. B.; Goetzman, E.; Chandel, N. S.; Denu, J. M.; Mrksich, M.; Bass, J., Circadian clock NAD⁺ cycle drives mitochondrial oxidative metabolism in mice. *Science* **2013**, *342*, (6158), 1243417.
22. Aggarwal, S.; Trehanpati, N.; Nagarajan, P.; Ramakrishna, G., The Clock-NAD(+) -Sirtuin connection in nonalcoholic fatty liver disease. *J Cell Physiol* **2022**, *237*, (8), 3164-3180.
23. Cermakian, N.; Sassone-Corsi, P., Multilevel regulation of the circadian clock. *Nature reviews. Molecular cell biology* **2000**, *1*, (1), 59-67.
24. Mohawk, J. A.; Green, C. B.; Takahashi, J. S., Central and peripheral circadian clocks in mammals. *Annu Rev Neurosci* **2012**, *35*, 445-62.
25. Bell-Pedersen, D.; Cassone, V. M.; Earnest, D. J.; Golden, S. S.; Hardin, P. E.; Thomas, T. L.; Zoran, M. J., Circadian rhythms from multiple oscillators: lessons from diverse organisms. *Nature reviews. Genetics* **2005**, *6*, (7), 544-56.
26. Dibner, C.; Schibler, U.; Albrecht, U., The mammalian circadian timing system: organization and coordination of central and peripheral clocks. *Annual review of physiology* **2010**, *72*, 517-49.
27. Damiola, F.; Le Minh, N.; Preitner, N.; Kornmann, B.; Fleury-Olela, F.; Schibler, U., Restricted feeding uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachiasmatic nucleus. *Genes & development* **2000**, *14*, (23), 2950-61.
28. Stokkan, K. A.; Yamazaki, S.; Tei, H.; Sakaki, Y.; Menaker, M., Entrainment of the circadian clock in the liver by feeding. *Science* **2001**, *291*, (5503), 490-3.

29. Yamazaki, S.; Numano, R.; Abe, M.; Hida, A.; Takahashi, R.; Ueda, M.; Block, G. D.; Sakaki, Y.; Menaker, M.; Tei, H., Resetting central and peripheral circadian oscillators in transgenic rats. *Science* **2000**, *288*, (5466), 682-5.
30. Balsalobre, A.; Brown, S. A.; Marcacci, L.; Tronche, F.; Kellendonk, C.; Reichardt, H. M.; Schutz, G.; Schibler, U., Resetting of circadian time in peripheral tissues by glucocorticoid signaling. *Science* **2000**, *289*, (5488), 2344-7.
31. Takahashi, J. S.; Hong, H. K.; Ko, C. H.; McDearmon, E. L., The genetics of mammalian circadian order and disorder: implications for physiology and disease. *Nature reviews. Genetics* **2008**, *9*, (10), 764-75.
32. Sinturel, F.; Gerber, A.; Mauvoisin, D.; Wang, J.; Gatfield, D.; Stubblefield, J. J.; Green, C. B.; Gachon, F.; Schibler, U., Diurnal Oscillations in Liver Mass and Cell Size Accompany Ribosome Assembly Cycles. *Cell* **2017**, *169*, (4), 651-663.e14.
33. Masri, S.; Sassone-Corsi, P., Plasticity and specificity of the circadian epigenome. *Nature neuroscience* **2010**, *13*, (11), 1324-9.
34. Hardin, P. E.; Hall, J. C.; Rosbash, M., Feedback of the *Drosophila* period gene product on circadian cycling of its messenger RNA levels. *Nature* **1990**, *343*, (6258), 536-40.
35. Lowrey, P. L.; Takahashi, J. S., Genetics of the mammalian circadian system: Photoc entrainment, circadian pacemaker mechanisms, and posttranslational regulation. *Annual review of genetics* **2000**, *34*, 533-562.
36. Takahashi, J. S., Transcriptional architecture of the mammalian circadian clock. *Nature reviews. Genetics* **2017**, *18*, (3), 164-179.
37. Lee, C.; Etchegaray, J. P.; Cagampang, F. R.; Loudon, A. S.; Reppert, S. M., Posttranslational mechanisms regulate the mammalian circadian clock. *Cell* **2001**, *107*, (7), 855-67.
38. Aryal, R. P.; Kwak, P. B.; Tamayo, A. G.; Gebert, M.; Chiu, P. L.; Walz, T.; Weitz, C. J., Macromolecular Assemblies of the Mammalian Circadian Clock. *Molecular cell* **2017**, *67*, (5), 770-782 e6.
39. Yamajuku, D.; Shibata, Y.; Kitazawa, M.; Katakura, T.; Urata, H.; Kojima, T.; Takayasu, S.; Nakata, O.; Hashimoto, S., Cellular DBP and E4BP4 proteins are critical for determining the period length of the circadian oscillator. *FEBS letters* **2011**, *585*, (14), 2217-22.
40. Laothamatas, I.; Rasmussen, E. S.; Green, C. B.; Takahashi, J. S., Metabolic and chemical architecture of the mammalian circadian clock. *Cell Chem Biol* **2023**, *30*, (9), 1033-1052.
41. Ueda, H. R.; Hayashi, S.; Chen, W.; Sano, M.; Machida, M.; Shigeyoshi, Y.; Iino, M.; Hashimoto, S., System-level identification of transcriptional circuits underlying mammalian circadian clocks. *Nature genetics* **2005**, *37*, (2), 187-92.
42. Mitsui, S.; Yamaguchi, S.; Matsuo, T.; Ishida, Y.; Okamura, H., Antagonistic role of E4BP4 and PAR proteins in the circadian oscillatory mechanism. *Genes & development* **2001**, *15*, (8), 995-1006.
43. Lowrey, P. L.; Shimomura, K.; Antoch, M. P.; Yamazaki, S.; Zemenides, P. D.; Ralph, M. R.; Menaker, M.; Takahashi, J. S., Positional syntenic cloning and functional characterization of the mammalian circadian mutation tau. *Science* **2000**, *288*, (5465), 483-92.
44. Meng, Q. J.; Logunova, L.; Maywood, E. S.; Gallego, M.; Lebiecki, J.; Brown, T. M.; Sládek, M.; Semikhodskii, A. S.; Glossop, N. R. J.; Piggins, H. D.; Chesham, J. E.; Bechtold, D. A.; Yoo, S. H.; Takahashi, J. S.; Virshup, D. M.; Boot-Handford, R. P.; Hastings, M. H.; Loudon, A. S. I., Setting clock speed in mammals: the CK1 epsilon tau mutation in mice accelerates circadian pacemakers by selectively destabilizing PERIOD proteins. *Neuron* **2008**, *58*, (1), 78-88.
45. Meng, Q. J.; Logunova, L.; Maywood, E. S.; Gallego, M.; Lebiecki, J.; Brown, T. M.; Sladek, M.; Semikhodskii, A. S.; Glossop, N. R. J.; Piggins, H. D.; Chesham, J. E.; Bechtold, D. A.; Yoo, S. H.; Takahashi, J. S.; Virshup, D. M.; Boot-Handford, R. P.; Hastings, M. H.; Loudon, A. S. I., Setting clock speed in mammals: the CK1 epsilon tau mutation in mice accelerates circadian pacemakers by selectively destabilizing PERIOD proteins. *Neuron* **2008**, *58*, (1), 78-88.
46. Shirogane, T.; Jin, J.; Ang, X. L.; Harper, J. W., SCFbeta-TRCP controls clock-dependent transcription via casein kinase 1-dependent degradation of the mammalian period-1 (Per1) protein. *The Journal of biological chemistry* **2005**, *280*, (29), 26863-72.
47. Reischl, S.; Vanselow, K.; Westermark, P. O.; Thierfelder, N.; Maier, B.; Herzog, H.; Kramer, A., Beta-TrCP1-mediated degradation of PERIOD2 is essential for circadian dynamics. *Journal of biological rhythms* **2007**, *22*, (5), 375-86.
48. Lamia, K. A.; Sachdeva, U. M.; DiTacchio, L.; Williams, E. C.; Alvarez, J. G.; Egan, D. F.; Vasquez, D. S.; Juguilon, H.; Panda, S.; Shaw, R. J.; Thompson, C. B.; Evans, R. M., AMPK regulates the circadian clock by cryptochrome phosphorylation and degradation. *Science* **2009**, *326*, (5951), 437-40.
49. Hirano, A.; Yumimoto, K.; Tsunematsu, R.; Matsumoto, M.; Oyama, M.; Kozuka-Hata, H.; Nakagawa, T.; Lanjakornsiripan, D.; Nakayama, K. I.; Fukada, Y., FBXL21 regulates oscillation of the circadian clock through ubiquitination and stabilization of cryptochromes. *Cell* **2013**, *152*, (5), 1106-18.

50. Yoo, S. H.; Mohawk, J. A.; Siepkka, S. M.; Shan, Y.; Huh, S. K.; Hong, H. K.; Kornblum, I.; Kumar, V.; Koike, N.; Xu, M.; Nussbaum, J.; Liu, X.; Chen, Z.; Chen, Z. J.; Green, C. B.; Takahashi, J. S., Competing E3 ubiquitin ligases govern circadian periodicity by degradation of CRY in nucleus and cytoplasm. *Cell* **2013**, *152*, (5), 1091-105.
51. Manjula, R.; Anuja, K.; Alcain, F. J., SIRT1 and SIRT2 Activity Control in Neurodegenerative Diseases. *Front Pharmacol* **2020**, *11*, 585821.
52. Sanders, B. D.; Jackson, B.; Marmorstein, R., Structural basis for sirtuin function: what we know and what we don't. *Biochimica et biophysica acta* **2010**, *1804*, (8), 1604-16.
53. Zhao, K.; Harshaw, R.; Chai, X.; Marmorstein, R., Structural basis for nicotinamide cleavage and ADP-ribose transfer by NAD(+)-dependent Sir2 histone/protein deacetylases. *Proceedings of the National Academy of Sciences of the United States of America* **2004**, *101*, (23), 8563-8.
54. Nogueiras, R.; Habegger, K. M.; Chaudhary, N.; Finan, B.; Banks, A. S.; Dietrich, M. O.; Horvath, T. L.; Sinclair, D. A.; Pfluger, P. T.; Tschöp, M. H., Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. *Physiol Rev* **2012**, *92*, (3), 1479-514.
55. Haigis, M. C.; Guarente, L. P., Mammalian sirtuins--emerging roles in physiology, aging, and calorie restriction. *Genes & development* **2006**, *20*, (21), 2913-21.
56. Finkel, T.; Deng, C. X.; Mostoslavsky, R., Recent progress in the biology and physiology of sirtuins. *Nature* **2009**, *460*, (7255), 587-91.
57. Ma, Q.; Wood, T. K., Protein acetylation in prokaryotes increases stress resistance. *Biochemical and biophysical research communications* **2011**, *410*, (4), 846-51.
58. Bai, W.; Zhang, X., Nucleus or cytoplasm? The mysterious case of SIRT1's subcellular localization. *Cell Cycle* **2016**, *15*, (24), 3337-3338.
59. Hoff, K. G.; Avalos, J. L.; Sens, K.; Wolberger, C., Insights into the sirtuin mechanism from ternary complexes containing NAD+ and acetylated peptide. *Structure* **2006**, *14*, (8), 1231-40.
60. Dali-Youcef, N.; Lagouge, M.; Froelich, S.; Koehl, C.; Schoonjans, K.; Auwerx, J., Sirtuins: the 'magnificent seven', function, metabolism and longevity. *Ann Med* **2007**, *39*, (5), 335-45.
61. Nakagawa, T.; Guarente, L., Sirtuins at a glance. *Journal of cell science* **2011**, *124*, (Pt 6), 833-8.
62. Singh, C. K.; Chhabra, G.; Ndiaye, M. A.; Garcia-Peterson, L. M.; Mack, N. J.; Ahmad, N., The Role of Sirtuins in Antioxidant and Redox Signaling. *Antioxid Redox Signal* **2018**, *28*, (8), 643-661.
63. North, B. J.; Marshall, B. L.; Borra, M. T.; Denu, J. M.; Verdin, E., The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. *Molecular cell* **2003**, *11*, (2), 437-44.
64. Vaquero, A.; Scher, M. B.; Lee, D. H.; Sutton, A.; Cheng, H. L.; Alt, F. W.; Serrano, L.; Sternglanz, R.; Reinberg, D., SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. *Genes & development* **2006**, *20*, (10), 1256-61.
65. Lin, J.; Sun, B.; Jiang, C.; Hong, H.; Zheng, Y., Sirt2 suppresses inflammatory responses in collagen-induced arthritis. *Biochemical and biophysical research communications* **2013**, *441*, (4), 897-903.
66. Pais, T. F.; Szegő, É, M.; Marques, O.; Miller-Fleming, L.; Antas, P.; Guerreiro, P.; de Oliveira, R. M.; Kasapoglu, B.; Outeiro, T. F., The NAD-dependent deacetylase sirtuin 2 is a suppressor of microglial activation and brain inflammation. *Embo j* **2013**, *32*, (19), 2603-16.
67. Morigi, M.; Perico, L.; Benigni, A., Sirtuins in Renal Health and Disease. *J Am Soc Nephrol* **2018**, *29*, (7), 1799-1809.
68. Wang, F.; Tong, Q., SIRT2 suppresses adipocyte differentiation by deacetylating FOXO1 and enhancing FOXO1's repressive interaction with PPARgamma. *Mol Biol Cell* **2009**, *20*, (3), 801-8.
69. Calnan, D. R.; Brunet, A., The FoxO code. *Oncogene* **2008**, *27*, (16), 2276-88.
70. Krishnan, J.; Danzer, C.; Simka, T.; Ukropec, J.; Walter, K. M.; Kumpf, S.; Mirtschink, P.; Ukropcova, B.; Gasperikova, D.; Pedrazzini, T.; Krek, W., Dietary obesity-associated Hif1alpha activation in adipocytes restricts fatty acid oxidation and energy expenditure via suppression of the Sirt2-NAD+ system. *Genes & development* **2012**, *26*, (3), 259-70.
71. Lombard, D. B.; Alt, F. W.; Cheng, H. L.; Bunkenborg, J.; Streeper, R. S.; Mostoslavsky, R.; Kim, J.; Yancopoulos, G.; Valenzuela, D.; Murphy, A.; Yang, Y.; Chen, Y.; Hirschey, M. D.; Bronson, R. T.; Haigis, M.; Guarente, L. P.; Farese, R. V., Jr.; Weissman, S.; Verdin, E.; Schwer, B., Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. *Molecular and cellular biology* **2007**, *27*, (24), 8807-14.
72. Hirschey, M. D.; Shimazu, T.; Goetzman, E.; Jing, E.; Schwer, B.; Lombard, D. B.; Grueter, C. A.; Harris, C.; Biddinger, S.; Ilkayeva, O. R.; Stevens, R. D.; Li, Y.; Saha, A. K.; Ruderman, N. B.; Bain, J. R.; Newgard, C. B.; Farese, R. V., Jr.; Alt, F. W.; Kahn, C. R.; Verdin, E., SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. *Nature* **2010**, *464*, (7285), 121-5.

73. Yang, Y.; Cimen, H.; Han, M. J.; Shi, T.; Deng, J. H.; Koc, H.; Palacios, O. M.; Montier, L.; Bai, Y.; Tong, Q.; Koc, E. C., NAD⁺-dependent deacetylase SIRT3 regulates mitochondrial protein synthesis by deacetylation of the ribosomal protein MRPL10. *The Journal of biological chemistry* **2010**, *285*, (10), 7417-29.
74. Wu, Q. J.; Zhang, T. N.; Chen, H. H.; Yu, X. F.; Lv, J. L.; Liu, Y. Y.; Liu, Y. S.; Zheng, G.; Zhao, J. Q.; Wei, Y. F.; Guo, J. Y.; Liu, F. H.; Chang, Q.; Zhang, Y. X.; Liu, C. G.; Zhao, Y. H., The sirtuin family in health and disease. *Signal Transduct Target Ther* **2022**, *7*, (1), 402.
75. He, J.; Hu, B.; Shi, X.; Weidert, E. R.; Lu, P.; Xu, M.; Huang, M.; Kelley, E. E.; Xie, W., Activation of the aryl hydrocarbon receptor sensitizes mice to nonalcoholic steatohepatitis by deactivating mitochondrial sirtuin deacetylase Sirt3. *Molecular and cellular biology* **2013**, *33*, (10), 2047-55.
76. Grabowska, W.; Sikora, E.; Bielak-Zmijewska, A., Sirtuins, a promising target in slowing down the ageing process. *Biogerontology* **2017**, *18*, (4), 447-476.
77. Haigis, M. C.; Mostoslavsky, R.; Haigis, K. M.; Fahie, K.; Christodoulou, D. C.; Murphy, A. J.; Valenzuela, D. M.; Yancopoulos, G. D.; Karow, M.; Blander, G.; Wolberger, C.; Prolla, T. A.; Weindruch, R.; Alt, F. W.; Guarente, L., SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. *Cell* **2006**, *126*, (5), 941-54.
78. Zaganjor, E.; Yoon, H.; Spinelli, J. B.; Nunn, E. R.; Laurent, G.; Keskinidis, P.; Sivaloganathan, S.; Joshi, S.; Notarangelo, G.; Mulei, S.; Chvasta, M. T.; Tucker, S. A.; Kalafut, K.; van de Ven, R. A. H.; Clish, C. B.; Haigis, M. C., SIRT4 is an early regulator of branched-chain amino acid catabolism that promotes adipogenesis. *Cell Rep* **2021**, *36*, (2), 109345.
79. Anderson, K. A.; Huynh, F. K.; Fisher-Wellman, K.; Stuart, J. D.; Peterson, B. S.; Douros, J. D.; Wagner, G. R.; Thompson, J. W.; Madsen, A. S.; Green, M. F.; Sivley, R. M.; Ilkayeva, O. R.; Stevens, R. D.; Backos, D. S.; Capra, J. A.; Olsen, C. A.; Campbell, J. E.; Muoio, D. M.; Grimsrud, P. A.; Hirschey, M. D., SIRT4 Is a Lysine Deacetylase that Controls Leucine Metabolism and Insulin Secretion. *Cell metabolism* **2017**, *25*, (4), 838-855 e15.
80. Jeong, S. M.; Xiao, C.; Finley, L. W.; Lahusen, T.; Souza, A. L.; Pierce, K.; Li, Y. H.; Wang, X.; Laurent, G.; German, N. J.; Xu, X.; Li, C.; Wang, R. H.; Lee, J.; Csibi, A.; Cerione, R.; Blenis, J.; Clish, C. B.; Kimmelman, A.; Deng, C. X.; Haigis, M. C., SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. *Cancer cell* **2013**, *23*, (4), 450-63.
81. Du, J.; Zhou, Y.; Su, X.; Yu, J. J.; Khan, S.; Jiang, H.; Kim, J.; Woo, J.; Kim, J. H.; Choi, B. H.; He, B.; Chen, W.; Zhang, S.; Cerione, R. A.; Auwerx, J.; Hao, Q.; Lin, H., Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. *Science* **2011**, *334*, (6057), 806-9.
82. Tan, M.; Peng, C.; Anderson, K. A.; Chhoy, P.; Xie, Z.; Dai, L.; Park, J.; Chen, Y.; Huang, H.; Zhang, Y.; Ro, J.; Wagner, G. R.; Green, M. F.; Madsen, A. S.; Schmiesing, J.; Peterson, B. S.; Xu, G.; Ilkayeva, O. R.; Muehlbauer, M. J.; Bralke, T.; Muhlhausen, C.; Backos, D. S.; Olsen, C. A.; McGuire, P. J.; Pletcher, S. D.; Lombard, D. B.; Hirschey, M. D.; Zhao, Y., Lysine glutarylation is a protein posttranslational modification regulated by SIRT5. *Cell metabolism* **2014**, *19*, (4), 605-17.
83. Nakagawa, T.; Lomb, D. J.; Haigis, M. C.; Guarente, L., SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. *Cell* **2009**, *137*, (3), 560-70.
84. Yang, L.; Ma, X.; He, Y.; Yuan, C.; Chen, Q.; Li, G.; Chen, X., Sirtuin 5: a review of structure, known inhibitors and clues for developing new inhibitors. *Sci China Life Sci* **2017**, *60*, (3), 249-256.
85. Liu, B.; Che, W.; Zheng, C.; Liu, W.; Wen, J.; Fu, H.; Tang, K.; Zhang, J.; Xu, Y., SIRT5: a safeguard against oxidative stress-induced apoptosis in cardiomyocytes. *Cell Physiol Biochem* **2013**, *32*, (4), 1050-9.
86. Rardin, M. J.; He, W.; Nishida, Y.; Newman, J. C.; Carrico, C.; Danielson, S. R.; Guo, A.; Gut, P.; Sahu, A. K.; Li, B.; Uppala, R.; Fitch, M.; Riiff, T.; Zhu, L.; Zhou, J.; Mulhern, D.; Stevens, R. D.; Ilkayeva, O. R.; Newgard, C. B.; Jacobson, M. P.; Hellerstein, M.; Goetzman, E. S.; Gibson, B. W.; Verdin, E., SIRT5 regulates the mitochondrial lysine succinylome and metabolic networks. *Cell metabolism* **2013**, *18*, (6), 920-33.
87. Nishida, Y.; Rardin, M. J.; Carrico, C.; He, W.; Sahu, A. K.; Gut, P.; Najjar, R.; Fitch, M.; Hellerstein, M.; Gibson, B. W.; Verdin, E., SIRT5 Regulates both Cytosolic and Mitochondrial Protein Malonylation with Glycolysis as a Major Target. *Molecular cell* **2015**, *59*, (2), 321-32.
88. Chen, X. F.; Tian, M. X.; Sun, R. Q.; Zhang, M. L.; Zhou, L. S.; Jin, L.; Chen, L. L.; Zhou, W. J.; Duan, K. L.; Chen, Y. J.; Gao, C.; Cheng, Z. L.; Wang, F.; Zhang, J. Y.; Sun, Y. P.; Yu, H. X.; Zhao, Y. Z.; Yang, Y.; Liu, W. R.; Shi, Y. H.; Xiong, Y.; Guan, K. L.; Ye, D., SIRT5 inhibits peroxisomal ACOX1 to prevent oxidative damage and is downregulated in liver cancer. *EMBO reports* **2018**, *19*, (5).
89. Liang, F.; Wang, X.; Ow, S. H.; Chen, W.; Ong, W. C., Sirtuin 5 is Anti-apoptotic and Anti-oxidative in Cultured SH-EP Neuroblastoma Cells. *Neurotox Res* **2017**, *31*, (1), 63-76.

90. Zhou, L.; Wang, F.; Sun, R.; Chen, X.; Zhang, M.; Xu, Q.; Wang, Y.; Wang, S.; Xiong, Y.; Guan, K. L.; Yang, P.; Yu, H.; Ye, D., SIRT5 promotes IDH2 desuccinylation and G6PD deglutarylation to enhance cellular antioxidant defense. *EMBO reports* **2016**, *17*, (6), 811-22.
91. Michishita, E.; McCord, R. A.; Berber, E.; Kioi, M.; Padilla-Nash, H.; Damian, M.; Cheung, P.; Kusumoto, R.; Kawahara, T. L.; Barrett, J. C.; Chang, H. Y.; Bohr, V. A.; Ried, T.; Gozani, O.; Chua, K. F., SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. *Nature* **2008**, *452*, (7186), 492-6.
92. Michishita, E.; McCord, R. A.; Boxer, L. D.; Barber, M. F.; Hong, T.; Gozani, O.; Chua, K. F., Cell cycle-dependent deacetylation of telomeric histone H3 lysine K56 by human SIRT6. *Cell Cycle* **2009**, *8*, (16), 2664-6.
93. Tennen, R. I.; Chua, K. F., Chromatin regulation and genome maintenance by mammalian SIRT6. *Trends Biochem Sci* **2011**, *36*, (1), 39-46.
94. Kawahara, T. L.; Rapicavoli, N. A.; Wu, A. R.; Qu, K.; Quake, S. R.; Chang, H. Y., Dynamic chromatin localization of Sirt6 shapes stress- and aging-related transcriptional networks. *PLoS genetics* **2011**, *7*, (6), e1002153.
95. Jia, G.; Su, L.; Singhal, S.; Liu, X., Emerging roles of SIRT6 on telomere maintenance, DNA repair, metabolism and mammalian aging. *Mol Cell Biochem* **2012**, *364*, (1-2), 345-50.
96. Wang, X. X.; Wang, X. L.; Tong, M. M.; Gan, L.; Chen, H.; Wu, S. S.; Chen, J. X.; Li, R. L.; Wu, Y.; Zhang, H. Y.; Zhu, Y.; Li, Y. X.; He, J. H.; Wang, M.; Jiang, W., SIRT6 protects cardiomyocytes against ischemia/reperfusion injury by augmenting FoxO3alpha-dependent antioxidant defense mechanisms. *Basic Res Cardiol* **2016**, *111*, (2), 13.
97. Kim, H. S.; Xiao, C.; Wang, R. H.; Lahusen, T.; Xu, X.; Vassilopoulos, A.; Vazquez-Ortiz, G.; Jeong, W. I.; Park, O.; Ki, S. H.; Gao, B.; Deng, C. X., Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. *Cell metabolism* **2010**, *12*, (3), 224-36.
98. Kugel, S.; Mostoslavsky, R., Chromatin and beyond: the multitasking roles for SIRT6. *Trends Biochem Sci* **2014**, *39*, (2), 72-81.
99. Pan, H.; Guan, D.; Liu, X.; Li, J.; Wang, L.; Wu, J.; Zhou, J.; Zhang, W.; Ren, R.; Zhang, W.; Li, Y.; Yang, J.; Hao, Y.; Yuan, T.; Yuan, G.; Wang, H.; Ju, Z.; Mao, Z.; Li, J.; Qu, J.; Tang, F.; Liu, G. H., SIRT6 safeguards human mesenchymal stem cells from oxidative stress by coactivating NRF2. *Cell Res* **2016**, *26*, (2), 190-205.
100. Abbotto, E.; Miro, C.; Piacente, F.; Salis, A.; Murolo, M.; Nappi, A.; Millo, E.; Russo, E.; Cichero, E.; Sturla, L.; Del Rio, A.; De Flora, A.; Nencioni, A.; Dentice, M.; Bruzzone, S., SIRT6 pharmacological inhibition delays skin cancer progression in the squamous cell carcinoma. *Biomed Pharmacother* **2023**, *166*, 115326.
101. Sociali, G.; Grozio, A.; Caffa, I.; Schuster, S.; Becherini, P.; Damonte, P.; Sturla, L.; Fresia, C.; Passalacqua, M.; Mazzola, F.; Raffaelli, N.; Garten, A.; Kiess, W.; Cea, M.; Nencioni, A.; Bruzzone, S., SIRT6 deacetylase activity regulates NAMPT activity and NAD(P)(H) pools in cancer cells. *FASEB J* **2019**, *33*, (3), 3704-3717.
102. Sociali, G.; Magnone, M.; Ravera, S.; Damonte, P.; Vigliarolo, T.; Von Holtey, M.; Vellone, V. G.; Millo, E.; Caffa, I.; Cea, M.; Parenti, M. D.; Del Rio, A.; Murone, M.; Mostoslavsky, R.; Grozio, A.; Nencioni, A.; Bruzzone, S., Pharmacological Sirt6 inhibition improves glucose tolerance in a type 2 diabetes mouse model. *FASEB J* **2017**, *31*, (7), 3138-3149.
103. Sharma, A.; Diecke, S.; Zhang, W. Y.; Lan, F.; He, C.; Mordwinkin, N. M.; Chua, K. F.; Wu, J. C., The role of SIRT6 protein in aging and reprogramming of human induced pluripotent stem cells. *The Journal of biological chemistry* **2013**, *288*, (25), 18439-47.
104. Mostoslavsky, R.; Chua, K. F.; Lombard, D. B.; Pang, W. W.; Fischer, M. R.; Gellon, L.; Liu, P.; Mostoslavsky, G.; Franco, S.; Murphy, M. M.; Mills, K. D.; Patel, P.; Hsu, J. T.; Hong, A. L.; Ford, E.; Cheng, H. L.; Kennedy, C.; Nunez, N.; Bronson, R.; Frendewey, D.; Auerbach, W.; Valenzuela, D.; Karow, M.; Hottiger, M. O.; Hursting, S.; Barrett, J. C.; Guarente, L.; Mulligan, R.; Demple, B.; Yancopoulos, G. D.; Alt, F. W., Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. *Cell* **2006**, *124*, (2), 315-29.
105. Li, L.; Shi, L.; Yang, S.; Yan, R.; Zhang, D.; Yang, J.; He, L.; Li, W.; Yi, X.; Sun, L.; Liang, J.; Cheng, Z.; Shi, L.; Shang, Y.; Yu, W., SIRT7 is a histone desuccinylase that functionally links to chromatin compaction and genome stability. *Nature communications* **2016**, *7*, 12235.
106. Barber, M. F.; Michishita-Kioi, E.; Xi, Y.; Tasselli, L.; Kioi, M.; Moqtaderi, Z.; Tennen, R. I.; Paredes, S.; Young, N. L.; Chen, K.; Struhl, K.; Garcia, B. A.; Gozani, O.; Li, W.; Chua, K. F., SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. *Nature* **2012**, *487*, (7405), 114-8.
107. Tsai, Y. C.; Greco, T. M.; Boonmee, A.; Miteva, Y.; Cristea, I. M., Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription. *Mol Cell Proteomics* **2012**, *11*, (2), M111.015156.
108. Hubbi, M. E.; Hu, H.; Kshitz; Gilkes, D. M.; Semenza, G. L., Sirtuin-7 inhibits the activity of hypoxia-inducible factors. *The Journal of biological chemistry* **2013**, *288*, (29), 20768-20775.

109. Sacks, F. M., The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia. *Curr Opin Lipidol* **2015**, *26*, (1), 56-63.
110. Vazquez, B. N.; Thackray, J. K.; Simonet, N. G.; Kane-Goldsmith, N.; Martinez-Redondo, P.; Nguyen, T.; Bunting, S.; Vaquero, A.; Tischfield, J. A.; Serrano, L., SIRT7 promotes genome integrity and modulates non-homologous end joining DNA repair. *EMBO J* **2016**, *35*, (14), 1488-503.
111. Vakhrusheva, O.; Smolka, C.; Gajawada, P.; Kostin, S.; Boettger, T.; Kubin, T.; Braun, T.; Bober, E., Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. *Circulation research* **2008**, *102*, (6), 703-10.
112. Raza, U.; Tang, X.; Liu, Z.; Liu, B., SIRT7: the seventh key to unlocking the mystery of aging. *Physiol Rev* **2024**, *104*, (1), 253-280.
113. Ryu, D.; Jo, Y. S.; Lo Sasso, G.; Stein, S.; Zhang, H.; Perino, A.; Lee, J. U.; Zeviani, M.; Romand, R.; Hottiger, M. O.; Schoonjans, K.; Auwerx, J., A SIRT7-dependent acetylation switch of GABPbeta1 controls mitochondrial function. *Cell metabolism* **2014**, *20*, (5), 856-869.
114. Dumbell, R.; Matveeva, O.; Oster, H., Circadian Clocks, Stress, and Immunity. *Front Endocrinol (Lausanne)* **2016**, *7*, 37.
115. Pavlova, M., Circadian Rhythm Sleep-Wake Disorders. *Continuum (Minneapolis, Minn)* **2017**, *23*, (4, Sleep Neurology), 1051-1063.
116. Smolensky, M. H.; Hermida, R. C.; Portaluppi, F., Circadian mechanisms of 24-hour blood pressure regulation and patterning. *Sleep Med Rev* **2017**, *33*, 4-16.
117. Nakahata, Y.; Sahar, S.; Astarita, G.; Kaluzova, M.; Sassone-Corsi, P., Circadian control of the NAD⁺ salvage pathway by CLOCK-SIRT1. *Science* **2009**, *324*, (5927), 654-7.
118. Ramsey, K. M.; Yoshino, J.; Brace, C. S.; Abrassart, D.; Kobayashi, Y.; Marcheva, B.; Hong, H. K.; Chong, J. L.; Buhr, E. D.; Lee, C.; Takahashi, J. S.; Imai, S.; Bass, J., Circadian clock feedback cycle through NAMPT-mediated NAD⁺ biosynthesis. *Science* **2009**, *324*, (5927), 651-4.
119. Rongvaux, A.; Andris, F.; Van Gool, F.; Leo, O., Reconstructing eukaryotic NAD metabolism. *BioEssays : news and reviews in molecular, cellular and developmental biology* **2003**, *25*, (7), 683-90.
120. Anderson, R. M.; Bitterman, K. J.; Wood, J. G.; Medvedik, O.; Cohen, H.; Lin, S. S.; Manchester, J. K.; Gordon, J. I.; Sinclair, D. A., Manipulation of a nuclear NAD⁺ salvage pathway delays aging without altering steady-state NAD⁺ levels. *The Journal of biological chemistry* **2002**, *277*, (21), 18881-90.
121. Zhou, B.; Zhang, Y.; Zhang, F.; Xia, Y.; Liu, J.; Huang, R.; Wang, Y.; Hu, Y.; Wu, J.; Dai, C.; Wang, H.; Tu, Y.; Peng, X.; Wang, Y.; Zhai, Q., CLOCK/BMAL1 regulates circadian change of mouse hepatic insulin sensitivity by SIRT1. *Hepatology* **2014**, *59*, (6), 2196-206.
122. Dioum, E. M.; Rutter, J.; Tuckerman, J. R.; Gonzalez, G.; Gilles-Gonzalez, M. A.; McKnight, S. L., NPAS2: a gas-responsive transcription factor. *Science* **2002**, *298*, (5602), 2385-7.
123. Rutter, J.; Reick, M.; Wu, L. C.; McKnight, S. L., Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. *Science* **2001**, *293*, (5529), 510-4.
124. Belden, W. J.; Dunlap, J. C., SIRT1 is a circadian deacetylase for core clock components. *Cell* **2008**, *134*, (2), 212-4.
125. Bellet, M. M.; Nakahata, Y.; Boudjelal, M.; Watts, E.; Mossakowska, D. E.; Edwards, K. A.; Cervantes, M.; Astarita, G.; Loh, C.; Ellis, J. L.; Vlasuk, G. P.; Sassone-Corsi, P., Pharmacological modulation of circadian rhythms by synthetic activators of the deacetylase SIRT1. *Proceedings of the National Academy of Sciences of the United States of America* **2013**, *110*, (9), 3333-8.
126. Chang, H. C.; Guarente, L., SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging. *Cell* **2013**, *153*, (7), 1448-60.
127. Masri, S.; Rigor, P.; Cervantes, M.; Ceglia, N.; Sebastian, C.; Xiao, C.; Roqueta-Rivera, M.; Deng, C.; Osborne, T. F.; Mostoslavsky, R.; Baldi, P.; Sassone-Corsi, P., Partitioning circadian transcription by SIRT6 leads to segregated control of cellular metabolism. *Cell* **2014**, *158*, (3), 659-72.
128. Sun, S.; Liu, Z.; Feng, Y.; Shi, L.; Cao, X.; Cai, Y.; Liu, B., Sirt6 deacetylase activity regulates circadian rhythms via Per2. *Biochemical and biophysical research communications* **2019**, *511*, (2), 234-238.
129. Liu, Z.; Qian, M.; Tang, X.; Hu, W.; Sun, S.; Li, G.; Zhang, S.; Meng, F.; Cao, X.; Sun, J.; Xu, C.; Tan, B.; Pang, Q.; Zhao, B.; Wang, Z.; Guan, Y.; Ruan, X.; Liu, B., SIRT7 couples light-driven body temperature cues to hepatic circadian phase coherence and gluconeogenesis. *Nat Metab* **2019**, *1*, (11), 1141-1156.
130. Feng, D.; Lazar, M. A., Clocks, metabolism, and the epigenome. *Molecular cell* **2012**, *47*, (2), 158-67.
131. Sahar, S.; Sassone-Corsi, P., Regulation of metabolism: the circadian clock dictates the time. *Trends in endocrinology and metabolism: TEM* **2012**, *23*, (1), 1-8.
132. Spiegel, K.; Tasali, E.; Leproult, R.; Van Cauter, E., Effects of poor and short sleep on glucose metabolism and obesity risk. *Nat Rev Endocrinol* **2009**, *5*, (5), 253-61.

133. Wijnen, H.; Young, M. W., Interplay of circadian clocks and metabolic rhythms. *Annual review of genetics* **2006**, *40*, 409-48.
134. Green, C. B.; Takahashi, J. S.; Bass, J., The meter of metabolism. *Cell* **2008**, *134*, (5), 728-42.
135. Eckel-Mahan, K. L.; Patel, V. R.; de Mateo, S.; Orozco-Solis, R.; Ceglia, N. J.; Sahar, S.; Dilag-Penilla, S. A.; Dyar, K. A.; Baldi, P.; Sassone-Corsi, P., Reprogramming of the circadian clock by nutritional challenge. *Cell* **2013**, *155*, (7), 1464-78.
136. Rutter, J.; Reick, M.; McKnight, S. L., Metabolism and the control of circadian rhythms. *Annu Rev Biochem* **2002**, *71*, 307-31.
137. Kaasik, K.; Lee, C. C., Reciprocal regulation of haem biosynthesis and the circadian clock in mammals. *Nature* **2004**, *430*, (6998), 467-71.
138. Tu, B. P.; McKnight, S. L., Metabolic cycles as an underlying basis of biological oscillations. *Nature reviews. Molecular cell biology* **2006**, *7*, (9), 696-701.
139. Kanfi, Y.; Naiman, S.; Amir, G.; Peshti, V.; Zinman, G.; Nahum, L.; Bar-Joseph, Z.; Cohen, H. Y., The sirtuin SIRT6 regulates lifespan in male mice. *Nature* **2012**, *483*, (7388), 218-21.
140. Milne, J. C.; Lambert, P. D.; Schenk, S.; Carney, D. P.; Smith, J. J.; Gagne, D. J.; Jin, L.; Boss, O.; Perni, R. B.; Vu, C. B.; Bemis, J. E.; Xie, R.; Disch, J. S.; Ng, P. Y.; Nunes, J. J.; Lynch, A. V.; Yang, H.; Galonek, H.; Israelian, K.; Choy, W.; Iffland, A.; Lavu, S.; Medvedik, O.; Sinclair, D. A.; Olefsky, J. M.; Jirousek, M. R.; Elliott, P. J.; Westphal, C. H., Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. *Nature* **2007**, *450*, (7170), 712-6.
141. Gertz, M.; Steegborn, C., Using mitochondrial sirtuins as drug targets: disease implications and available compounds. *Cell Mol Life Sci* **2016**, *73*, (15), 2871-96.
142. Abbotto, E.; Scarano, N.; Piacente, F.; Millo, E.; Cichero, E.; Bruzzone, S., Virtual Screening in the Identification of Sirtuins' Activity Modulators. *Molecules* **2022**, *27*, (17).
143. Bruzzone, S.; Parenti, M. D.; Grozio, A.; Ballestrero, A.; Bauer, I.; Del Rio, A.; Nencioni, A., Rejuvenating sirtuins: the rise of a new family of cancer drug targets. *Curr Pharm Des* **2013**, *19*, (4), 614-23.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.